DACPLAT en es it fr

DACPLAT Brand names, DACPLAT Analogs

DACPLAT Brand Names Mixture

  • No information avaliable

DACPLAT Chemical_Formula




DACPLAT fda sheet


DACPLAT msds (material safety sheet)


DACPLAT Synthesis Reference

No information avaliable

DACPLAT Molecular Weight

395.27 g/mol

DACPLAT Melting Point

No information avaliable

DACPLAT H2O Solubility

No information avaliable




No information avaliable

DACPLAT Dosage Forms

No information avaliable

DACPLAT Indication

For the treatment of malignant neoplasm of colon, rectum, and ovary

DACPLAT Pharmacology

Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

DACPLAT Absorption

No information avaliable

DACPLAT side effects and Toxicity

No information avaliable

DACPLAT Patient Information

Patients and patientsí caregivers should be informed of the expected side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects, and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.

Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.

Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.

DACPLAT Organisms Affected

Humans and other mammals